|Solubility:||25 mg/mL in DMSO|
|Long-term Storage:||at -20℃|
|HPLC:||Shows Min > 99% purity|
|H-NMR:||Consistent with structure|
|Description:||BMS-813160 is the first dual CCR2/CCR5 antagonist to enter clinical development for cardiovascular.|
|Stability and Solubility Advice:|| Information concerning product stability, particularly in solution, has rarely been reported and in most cases we can only offer a general guide.
We recommend that stock solutions, once prepared, are stored aliquoted in tightly sealed vials at -20°C or below and used within 1 month.